- Press Release -

Rockville, Md. The global peptide based metabolic disorders therapeutics market is set to exceed US$ 8 Bn by 2022 on robust growth, according to Fact.MR, as rising metabolic disorder rates push the development of new peptide treatments. Efficacy, safety, easy synchronization and stability, along with steady drug-discovery innovation and heavier healthcare investment, are working in the market's favour.

North America leads by revenue and growth, liraglutide is the leading drug, and hospital pharmacies carry most sales. Online pharmacies are the fastest-growing channel.

Drugs, Channels and Regions

Liraglutide dominates by drug class on revenue, growing robustly if more slowly than its peers, while exenatide and other classes expand at similar rates, with exenatide holding the larger share of the two. On distribution, hospital pharmacies hold the largest revenue share, retail pharmacies rank second with faster growth, and online pharmacies grow fastest at an 11.8% CAGR from a smaller base.

North America leads by revenue and grows fastest at a 10.6% CAGR, supported by technological progress and healthcare investment, while Asia Pacific excluding Japan grows at a similar pace from a base less than a third of North America's.

Disease Burden Drives Demand

The market runs on clinical need. As metabolic disorders become more common, the case for new peptide-based treatments strengthens, and rising investment from biotech and pharmaceutical companies keeps the pipeline moving through the forecast period.

Suppliers and Their Playbook

The field brings together peptide specialists and large pharmaceutical companies.

• Bachem Holding AG, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, and CordenPharma International are among the key players in the report.

Reading the Market for Decisions

For drug makers, growth favours established peptide drugs and a stronger online channel. Investors get a market with robust, disease-led demand. Procurement and pharmacy teams can plan around liraglutide carrying volume, hospital pharmacies leading distribution, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global peptide based metabolic disorders therapeutics market for the 2017 to 2022 forecast period, with segmentation by drug class, distribution channel and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the peptide based metabolic disorders therapeutics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.